Purdue Pharma Seeks Court Nod for 7.4 Billion Dollar Opioid Settlement in Bankruptcy Overhaul Plan

---

Full Story

Purdue Pharma, the maker of OxyContin, petitioned a bankruptcy judge on Wednesday to greenlight a $7.4 billion settlement resolving lawsuits over its role in the U.S. opioid crisis. The restructuring would channel funds to victims and states, marking a potential close to years of litigation against the Sackler family firm. Opioids, prescribed for pain since the 1990s, spiraled into addiction epidemics claiming thousands yearly.

The crisis, declared a public health emergency in 2017, traces to aggressive marketing of extended-release pills. Purdue’s 2007 guilty plea for misbranding set precedents for accountability.

MEDIA REPORTING

See how news sources on all sides are covering this story.

Left 38% | Right 23% | Center 31% | Unrated 8%

The Context

The plan forgives Sackler claims in exchange for payouts, drawing fire from holdout attorneys general. Bankruptcy court in New York oversees the Chapter 11 filing from 2019.

Funds target treatment programs and survivor support, per the 1999 SUPPORT Act’s framework. Distribution prioritizes hardest-hit rural counties.

Critics allege the deal shields personal assets insufficiently, echoing Enron-era restructurings. Proponents stress it unlocks relief faster than trials.

DEA schedules classify opioids tightly, yet prescriptions peaked at 255 million in 2012. Harm reduction, from naloxone to clean needles, gains traction.

Advocates for victims welcome cash for rehab, easing fiscal strains on communities. Pharma defenders argue innovation suffers under liability fears.

Some states push for transparency in Sackler transfers. Others prioritize swift disbursal to fund prevention education.